iStock_000013442184_smaller.jpg
iStock_000012327220_smaller.jpg
iStock_000054355510_smaller.jpg
iStock_000017531127_smaller.jpg
iStock_000013442184_smaller.jpg

introducing a new class of antibiotics


SCROLL DOWN

introducing a new class of antibiotics


BKG Pharma is a privately held Danish biopharmaceutical company exclusively committed to the development of novel antibiotics against multidrug-resistant (MDR) bacteria. We kill superbugs for a living. 

Through our groundbreaking research and development program we have identified and developed an entire new class of small molecule antibiotics with a novel mechanism of action independent of all known resistance mechanism.

iStock_000012327220_smaller.jpg

making antibiotics that could change the future


making antibiotics that could change the future


Resistance to chemotherapy is a common clinical problem in patients with infectious diseases. During treatment of infections the anti-infective cells are often found to be refractory to a variety of drugs that have different structures and functions. This phenomenon has been termed multi-drug resistance (MDR).

The incidence of the multiple antimicrobial resistance of bacteria which cause infections, especially in hospitals and intensive care units, is increasing, and finding micro-organisms resistant to more than 10 different antibiotics is not unusual. Despite advances in antimicrobial therapies and infection strategies, the emergence of MDR is developing into an real emergency situation.

It is estimated that by 2050 more than 10 million people may die annually from MDR infections thereby making MDR infections more deadly than cancer. In particular infections due to MDR, Gram-negative pathogens are responsible for high mortality rates and leave few effective antimicrobial treatment options.

If we are to win the war against superbugs it is crucially important that new antibiotics are developed and brought into clinical practice. 

By introducing an entire new class of small molecule antibiotics with strong clinical potential BKG Pharma is breaking new ground. 

We believe that we are making antibiotics that potentially could change the world. 

 

iStock_000054355510_smaller.jpg

the BKG antibiotic program


the BKG antibiotic program


BKG Pharma's Antibiotic Program provides drug candidates with a strong clinical potential, alone or in combination with traditional antibiotics, to optimize therapeutic treatment success.

Our candidates show high efficacy and specificity when tested against large panels of clinically relevant Gram-positive and Gram-negative isolates, including ESKAPE pathogens and other clinically relevant MDR strains. 

The effect comprises both a killing effect when used alone, and the effect of reversing microbial resistance to common antibiotics when used in combination at sub-MIC concentrations (synergism).

With promising preclinical data demonstrating a high level of safety and tolerance and excellent PK/PD properties, BKG Pharma is preparing to advance its first drug-candidates into clinical trials.

 

 
 
iStock_000017531127_smaller.jpg

the BKG platform for the future


the BKG platform for the future


With a genuinely groundbreaking research and development program and a strong IP portfolio BKG Pharma has created an extraordinary platform for future discovery and development of potential first-in-class small molecule antibiotics against MDR resistant infections. 

Based on QSAR analysis of the mode of action of existing drug candidates, novel compounds are continually being intelligently designed. By applying our method of intelligent exploration of the proprietary pool of compounds, we have already succeeded in discovering and developing new frontrunner compounds targeting selected MDR Gram-negative bacteria.